Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.53 |
| ▸ | CTSK | P43235 | 12/20 | 0.51 |
| ▸ | CTSS | P25774 | 6/20 | 0.51 |
| ▸ | PPARG | P37231 | 2/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.46 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13365298 | 1.00 | PPARA (0.53) | PPARACTSKCTSSPPARGITGB3 | |
| SCHEMBL805173 | 1.00 | PPARA (0.53) | PPARACTSKCTSSPPARGITGB3 | |
| SCHEMBL31407501 | 0.96 | PPARA (0.52) | PPARACTSKCTSSPPARGITGB3 | |
| SCHEMBL24633954 | 0.91 | PPARA (0.55) | PPARACTSKCTSSPPARGITGB3 | |
| SCHEMBL21837472 | 0.91 | PPARA (0.55) | PPARACTSKCTSSPPARGITGB3 | |
| SCHEMBL21837471 | 0.91 | PPARA (0.55) | PPARACTSKCTSSPPARGITGB3 | |
| SCHEMBL7761525 | 0.90 | PPARA (0.47) | PPARACTSKCTSSPPARGITGB3 | |
| SCHEMBL14174566 | 0.87 | PPARA (0.43) | PPARACTSKCTSSPPARGITGB3 | |
| SCHEMBL15243753 | 0.87 | CTSK (0.53) | PPARACTSKCTSSPPARGITGB3 | |
| SCHEMBL16558033 | 0.87 | CTSK (0.49) | PPARACTSKCTSSPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PEPTIDREAM INC (JP) | 2026-01-15 | — | — | US | disclosed |
| EP-4534524-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PeptiDream Inc. (JP) | 2025-04-09 | — | — | EP | disclosed |
| US-20230348493-A1 | COMPOUND FOR ADJUSTING ACTIVITY OF NMDA RECEPTOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | BEIJING GREATWAY PHARMACEUTICAL TECHNOLOGY CO. LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| EP-4137496-A1 | COMPOUND FOR ADJUSTING ACTIVITY OF NMDA RECEPTOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Beijing Greatway Pharmaceutical Technology Co., Ltd. (CN) | 2023-02-22 | — | — | EP | disclosed |
| US-9771338-B2 | 1,2,4-oxadiazole derivatives as immunomodulators | Auirgene Discovery Technologies Limited (IN) | 2017-09-26 | — | — | US | disclosed |
| EP-2970224-B1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS INC (US) | 2017-09-06 | — | — | EP | disclosed |
| US-20170231956-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2017-08-17 | — | — | US | disclosed |
| WO-2017101851-A1 | ACYLSULFONAMIDE DERIVATIVES FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS | UNITY BIOTECHNOLOGY, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
| US-20170101386-A1 | 1,2,4-Oxadiazole Derivatives as Immunomodulators | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2017-04-13 | — | — | US | disclosed |
| US-9579304-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | Aptinyx, Inc. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150073024-A1 | 1,2,4-Oxadiazole Derivatives as Immunomodulators | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-03-12 | — | — | US | disclosed |
| WO-2015033299-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS IMMUNOMODULATORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-03-12 | — | — | WO | disclosed |
| WO-2015033301-A1 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE DERIVATIVES AS IMMUNOMODULATORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-03-12 | — | — | WO | disclosed |
| WO-2014152134-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014120783-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | NAUREX, INC. (US) | 2014-08-07 | — | — | WO | disclosed |
| WO-2013123444-A1 | SULFONYL COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN | AMGEN INC. (US) | 2013-08-22 | — | — | WO | disclosed |
| US-8431563-B2 | Compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-09-06 | — | — | US | disclosed |
| WO-2012027261-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| US-20030105097-A1 | Alkylamide compounds | PFIZER INC. | 2003-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348493-A1 | COMPOUND FOR ADJUSTING ACTIVITY OF NMDA RECEPTOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | GRIN1, GRIN3A, GRIN2C | PPARA 1013/4885CTSK 4179/4885CTSS 4433/4885 |
| US-20150073024-A1 | 1,2,4-Oxadiazole Derivatives as Immunomodulators | CD274, PDCD1, PDCD1LG2 | PPARA 660/4885CTSK 3252/4885CTSS 4217/4885 |
| US-20170231956-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | PPARA 1244/4885CTSK 4114/4885CTSS 4304/4885 |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | NSUN3, BCAT1, SLC43A1 | PPARA 2794/4885CTSK 4661/4885CTSS 4022/4885 |
| US-20030105097-A1 | Alkylamide compounds | CBR1, CNR1, CBR3 | PPARA 3440/4885CTSK 4543/4885CTSS 3582/4885 |
| US-20170101386-A1 | 1,2,4-Oxadiazole Derivatives as Immunomodulators | CD274, PDCD1, PDCD1LG2 | PPARA 660/4885CTSK 3252/4885CTSS 4217/4885 |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | GCKR, GCK, SLC5A2 | PPARA 955/4885CTSK 990/4885CTSS 3395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.